Compare NUVL & ATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | ATR |
|---|---|---|
| Founded | 2017 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Plastic Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.2B |
| IPO Year | 2021 | 1995 |
| Metric | NUVL | ATR |
|---|---|---|
| Price | $123.40 | $115.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 4 |
| Target Price | $134.75 | ★ $170.25 |
| AVG Volume (30 Days) | ★ 2.5M | 435.1K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | N/A | ★ 6.51 |
| EPS | N/A | ★ 1.12 |
| Revenue | N/A | ★ $3,777,181,000.00 |
| Revenue This Year | N/A | $5.18 |
| Revenue Next Year | $1,239.49 | $4.98 |
| P/E Ratio | ★ N/A | $103.48 |
| Revenue Growth | N/A | ★ 5.42 |
| 52 Week Low | $71.14 | $103.23 |
| 52 Week High | $123.62 | $164.28 |
| Indicator | NUVL | ATR |
|---|---|---|
| Relative Strength Index (RSI) | 66.60 | 46.26 |
| Support Level | $97.71 | $111.55 |
| Resistance Level | N/A | $125.35 |
| Average True Range (ATR) | 4.37 | 2.84 |
| MACD | 1.97 | 0.47 |
| Stochastic Oscillator | 99.39 | 62.75 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.